Roger Unger

Q: What Schools Are Affiliated With Roger Unger

Roger Unger is affiliated with the following schools: Tohoku University, Yale University, University of Geneva, University of Texas Southwestern Medical Center

Roger Unger's AcademicInfluence.com Rankings

Roger Unger

Philosophy

#1845

World Rank

#3270

Historical Rank

#696

USA Rank

Logic

#336

World Rank

#666

Historical Rank

#137

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Roger Unger Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Roger H. Unger was an American physician known for his studies of the physiology of pancreatic islets. In particular the elucidation of the roles of insulin and glucagon in the regulation of normal blood glucose homeostasis and in the pathogenesis of diabetes, and the establishment of glucagon as a hormone. He was the Touchstone/West Distinguished Chair in Diabetes Research at University of Texas Southwestern Medical Center.

(See a Problem?)

Roger Unger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Lipotoxic heart disease in obese rats: implications for human obesity. (2000) (1287)
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications (1995) (1096)
Fatty acid-induced β cell apoptosis: A link between obesity and diabetes (1998) (1074)
Studies of pancreatic alpha cell function in normal and diabetic subjects. (1970) (876)
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. (1994) (795)
Lipotoxic diseases. (2002) (707)
Direct antidiabetic effect of leptin through triglyceride depletion of tissues. (1997) (706)
Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. (2003) (670)
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. (1968) (621)
Pancreatic glucagon secretion in normal and diabetic subjects. (1969) (619)
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. (1970) (610)
Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study (2007) (592)
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. (2012) (574)
THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS (1975) (542)
Lipid homeostasis, lipotoxicity and the metabolic syndrome. (2010) (535)
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. (1998) (463)
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. (2001) (455)
Diseases of liporegulation: new perspective on obesity and related disorders (2001) (442)
Regulation of fatty acid homeostasis in cells: novel role of leptin. (1999) (439)
FUNCTIONAL SUBDIVISION OF ISLETS OF LANGERHANS AND POSSIBLE ROLE OF D CELLS (1975) (436)
Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging (2003) (422)
Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. (1988) (421)
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. (1997) (401)
Lipid overload and overflow: metabolic trauma and the metabolic syndrome (2003) (391)
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. (1998) (382)
Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity (2010) (376)
Entero-insular axis. (1969) (375)
Adiposity of the Heart*, Revisited (2006) (372)
Novel Form of Lipolysis Induced by Leptin* (1999) (371)
Lipoapoptosis: its mechanism and its diseases. (2002) (367)
Somatostatinoma syndrome. Biochemical, morphologic and clinical features. (1979) (355)
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. (1967) (342)
Insulin within islets is a physiologic glucagon release inhibitor. (1984) (320)
Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. (1996) (318)
Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice (2011) (317)
Leptin therapy in insulin-deficient type I diabetes (2010) (313)
A glucagon-secreting alpha-cell carcinoma of the pancreas. (1966) (306)
Glucagon levels and metabolic effects in fasting man. (1970) (301)
The effects of total starvation upon the levels of circulating glucagon and insulin in man. (1963) (297)
Role of nitric oxide in obesity-induced beta cell disease. (1997) (297)
Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. (1968) (297)
Quantitation of Endocrine Cell Content in the Pancreas of Nondiabetic and Diabetic Humans (1982) (293)
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes (1985) (291)
Diabetic hyperglycemia: link to impaired glucose transport in pancreatic beta cells. (1991) (286)
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. (2000) (280)
Glucagon physiology and pathophysiology. (1971) (280)
Glucagon antibodies and an immunoassay for glucagon. (1961) (277)
Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. (1976) (271)
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. (1995) (269)
Diabetes and apoptosis: lipotoxicity (2009) (269)
Glucagon and the Insulin:Glucagon Ratio in Diabetes and Other Catabolic Illnesses (1971) (268)
Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats* (1998) (262)
Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. (2007) (260)
Glucagon physiology and pathophysiology in the light of new advances (1985) (254)
Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. (1962) (251)
Glucagon and the A cell: physiology and pathophysiology (second of two parts). (1981) (251)
The effect of experimental insulin deficiency on glucagon secretion. (1971) (249)
Comparison of Effects of High and Low Carbohydrate Diets on Plasma Lipoproteins and Insulin Sensitivity in Patients With Mild NIDDM (1992) (247)
Physiology and pathophysiology of glucagon. (1976) (240)
Reversing adipocyte differentiation: implications for treatment of obesity. (1999) (239)
Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. (1997) (239)
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. (1998) (238)
Paracrinology of islets and the paracrinopathy of diabetes (2010) (238)
Glucagon-stimulating activity of 20 amino acids in dogs. (1972) (238)
Rapid transformation of white adipocytes into fat-oxidizing machines (2004) (236)
Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. (1982) (224)
Glucagon: role in the hyperglycemia of diabetes mellitus. (1975) (224)
Making insulin-deficient type 1 diabetic rodents thrive without insulin (2008) (223)
Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog. (1978) (220)
A novel leptin receptor isoform in rat (1996) (220)
The physiology of cellular liporegulation. (2003) (216)
Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. (1973) (214)
Role of glucagon in the pathogenesis of diabetes: the status of the controversy. (1978) (212)
Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. (1978) (212)
Liporegulation in Diet-induced Obesity (2001) (211)
Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. (1990) (211)
Effects of Starvation on Plasma Pancreatic Glucagon in Normal Man (1969) (210)
THE HYPOGLYCEMIC ACTION OF KETONES. II. EVIDENCE FOR A STIMULATORY FEEDBACK OF KETONES ON THE PANCREATIC BETA CELLS. (1964) (204)
The Banting Memorial Lecture 1975: Diabetes and the Alpha Cell (1976) (198)
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. (1969) (196)
Increased Lipogenic Capacity of the Islets of Obese Rats: A Role in the Pathogenesis of NIDDM (1997) (193)
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. (1968) (193)
More Direct Evidence for a Malonyl-CoA–Carnitine Palmitoyltransferase I Interaction as a Key Event in Pancreatic β-Cell Signaling (1994) (193)
Abnormal pancreatic alpha-cell function in bacterial infections. (1973) (186)
PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue (2002) (180)
Noninvasive quantification of pancreatic fat in humans. (2009) (178)
Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide. (1977) (173)
Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. (1978) (170)
Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. (1979) (168)
Identification of glucagon in the gastrointestinal tract. (1975) (165)
Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. (1992) (164)
Gene expression profile of rat adipose tissue at the onset of high-fat-diet obesity. (2002) (163)
Glucagon and the A cell: physiology and pathophysiology (first two parts). (1981) (162)
Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. (2005) (156)
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. (1990) (156)
Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. (2004) (155)
Special Comment: Meticulous Control of Diabetes: Benefits, Risks, and Precautions (1982) (154)
Glucagon Antibodies and Their Use for Immunoassay for Glucagon.∗ (1959) (154)
Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. (2005) (151)
Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. (1981) (148)
The role of aminogenic glucagon secretion in blood glucose homeostasis. (1969) (147)
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition (2004) (146)
Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. (1980) (145)
The role of leptin resistance in the lipid abnormalities of aging (2001) (145)
β-Cell Function in Normal Rats Made Chronically Hyperleptinemic by Adenovirus-Leptin Gene Therapy (1997) (143)
Measurements of somatostatin-like immunoreactivity in plasma. (1978) (143)
Letter: Glucagon in pathogenesis of diabetes. (1975) (142)
The influence of the antecedent diet upon glucagon and insulin secretion. (1971) (139)
Metabolic manifestations of insulin deficiency do not occur without glucagon action (2012) (138)
Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. (1982) (137)
Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome (2008) (135)
Biochemical Mechanism of Lipid-induced Impairment of Glucose-stimulated Insulin Secretion and Reversal with a Malate Analogue* (2004) (132)
Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics. (1975) (131)
The effect of alanine on glucagon secretion. (1971) (129)
A morphological basis for intercellular communication between alpha- and beta-cells in the endocrine pancreas. (1975) (128)
Control of Pancreatic Glucagon Secretion by Glucose (1969) (128)
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. (1996) (127)
Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice. (2017) (124)
Possible Roles of the Pancreatic D-cell in the Normal and Diabetic States (1977) (123)
Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. (1974) (121)
HYPERGLUCAGONÆMIA AFTER BURNS (1974) (121)
How obesity causes diabetes in Zucker diabetic fatty rats (1997) (120)
The effects of gastrin, gastric inhibitory polypeptide, secretin, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas. (1977) (119)
Insig-1 “brakes” lipogenesis in adipocytes and inhibits differentiation of preadipocytes (2003) (119)
Pancreatic alpha-cell function in trauma. (1974) (119)
Effect on plasma free fatty acids on plasma glucagon and serum insulin concentrations. (1968) (118)
Glucagon is the key factor in the development of diabetes (2016) (118)
Specific endocrine and hormonal receptor changes associated with liver regeneration in adult rats. (1975) (117)
Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells (1998) (116)
Severe Diabetes Induced in Subtotally Depancreatized Dogs by Sustained Hyperglycemia (1988) (115)
Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. (2008) (114)
Effects of secretin on insulin and glucagon in portal and peripheral blood in man. (1966) (114)
Distribution of immunoassayable glucagon in gastrointestinal tissues. (1966) (113)
Pancreatic immunoreactive somatostatin release. (1977) (113)
Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. (2004) (112)
Regulation of beta-cell glucose transporter gene expression. (1990) (110)
Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. (1962) (105)
OB-Rb gene transfer to leptin-resistant islets reverses diabetogenic phenotype. (1998) (105)
Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. (1998) (104)
Glucagon; molecular physiology, clinical and therapeutic implications (1972) (102)
Alpha- and beta-cell interrelationships in health and disease. (1974) (101)
Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. (2005) (100)
The riddle of tumor hypoglycemia. (1966) (98)
Pronase Effect on Pancreatic Beta Cell Secretion and Morphology (1973) (96)
The effect of exercise on glucagon secretion. (1972) (96)
Hyperleptinemia: protecting the heart from lipid overload. (2005) (95)
Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling. (2000) (95)
Binding and biologic activity of glucagon in liver cell membranes of chronically hyperglucagonemic rats. (1977) (94)
Abnormal Alpha Cell Function in Diabetics Response to Insulin (1972) (93)
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. (1974) (93)
Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs. (1975) (92)
IDENTIFICATION OF INSULIN AND GLUGACON IN A BRONCHOGENIC METASTASIS. (1964) (91)
Changes in Glucagon Levels After Four to Five Weeks of Glucoregulation by Portable Insulin Infusion Pumps (1979) (91)
Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. (2006) (91)
Reduced beta-cell glucose transporter in new onset diabetic BB rats. (1990) (89)
Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. (2007) (89)
Large glucagon immunoreactivity in extracts of pancreas. (1970) (88)
Incubation Damage in the Radioimmunoassay for Human Plasma Glucagon and Its Prevention with “Trasylol” (1968) (88)
Expression of reg/PSP, a pancreatic exocrine gene: relationship to changes in islet beta-cell mass. (1991) (87)
Pancreatic Steatosis and Its Relationship to β-Cell Dysfunction in Humans (2012) (87)
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence (1995) (87)
A New Diagnostic Procedure for Mild Diabetes Mellitus: Evaluation of an Intravenous Tolbutamide Response Test (1958) (87)
Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment. (1982) (86)
Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. (1999) (85)
Glucagon-like Polypeptides in Canine Brain (1979) (84)
Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway (2015) (84)
Demonstration and characterization of a second fraction of glucagon-like immunoreactivity in jejunal extracts. (1968) (83)
Identification of glucagon-producing cells (A cells) in dog gastric mucosa (1976) (83)
Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. (2002) (83)
Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells (2014) (82)
THE RELATIONSHIP BETWEEN THE MECHANISM OF ACTION OF THE SULFONYLUREAS AND THE SECRETION OF INSULIN INTO THE PORTAL CIRCULATION (1959) (82)
Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. (1997) (82)
Effect of Insulin on the Exaggerated Glucagon Response to Arginine Stimulation in Diabetes Mellitus (1976) (82)
Insulin-Glucagon Relationships in the Defense Against Hypoglycemia (1983) (81)
The antilipolytic action of insulin in obese subjects with resistance to its glucoregulatory action. (1984) (80)
Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. (1990) (79)
Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients. (1979) (79)
Effect of secretin on insulin secretion. (1966) (79)
Adenovirus-mediated overexpression of uncoupling protein-2 in pancreatic islets of Zucker diabetic rats increases oxidative activity and improves beta-cell function. (1999) (78)
Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. (1998) (78)
The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity. (1973) (78)
Serum glucagon and insulin levels and their relationship to blood glucose values in patients with acute myocardial infarction and acute coronary insufficiency. (1974) (78)
Morphine-induced hyperglycemia: role of insulin and glucagon. (1980) (77)
Leptin physiology: a second look (2000) (75)
The response of plasma somatostatin-like immunoreactivity to nutrients in normal and alloxan diabetic dogs. (1978) (75)
GLUT2 Expression and Function in β-cells of GK rats with NIDDM: Dissociation Between Reductions in Glucose Transport and Glucose-Stimulated Insulin Secretion (1993) (75)
The effect of adrenergic blockade on exercise-induced hyperglucagonemia. (1974) (75)
Active hepatic glycogen synthesis from gluconeogenic precursors despite high tissue levels of fructose 2,6-bisphosphate. (1986) (75)
The physiologic significance of the secretion of endogenous insulin into the portal circulation. I. Comparison of the effects of glucagon-free insulin adminstered via the portal vein and via a peripheral vein on the magnitude of hypoglycemia and peripheral glucose utilization. (1958) (74)
Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. (1987) (74)
The standard two-hour oral glucose tolerance test in the diagnosis of diabetes mellitus in subjects without fasting hyperglycemia. (1957) (73)
Effect upon Insulin Secretion of Physiologic Doses of Glucagon Administered via the Portal Vein (1967) (72)
The Hyperleptinemia of Obesity—Regulator of Caloric Surpluses (2004) (72)
Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia. (1984) (71)
Glucagon and the A cells. (2010) (71)
Insulin and Glucagon: Partners for Life (2017) (69)
Metabolic and hormonal interactions between muscle and adipose tissue (2004) (69)
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. (1998) (68)
Gastric A-cell function in insulin-deprived depancreatized dogs. (1976) (68)
Fatty diabetic lung: altered alveolar structure and surfactant protein expression. (2010) (67)
Evidence for a role of endogenous insulin and glucagon in the regulation of potassium homeostasis. (1973) (67)
Evidence for marked sensitivity to the antilipolytic action of insulin in obese maturity-onset diabetics. (1979) (66)
Hepatic Autophagy in Uncontrolled Experimental Diabetes and Its Relationships to Insulin and Glucagon (1974) (66)
Cell contacts in human islets of Langerhans. (1975) (65)
Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. (1966) (65)
Hypothesis: physiologic role of pancreatic somatostatin and the contribution of D-cell disorders to diabetes mellitus. (1977) (64)
Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. (1997) (63)
Comparison of response to intravenously administered sodium tolbutamide in milk diabetic and non-diabetic subjects. (1958) (63)
Suppressive effect of secretin upon pancreatic alpha cell function. (1972) (62)
Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. (1985) (62)
A Simplified Method Using Somatostatin to Assess In Vivo Insulin Resistance over a Range of Obesity (1979) (61)
Evidence for the Hormonal Status of Somatostatin in Man (1981) (60)
Pancreatic Steatosis and Its Relationship to b-Cell Dysfunction in Humans Racial and ethnic variations (2012) (59)
Carbohydrate Metabolism in Pregnancy: XI. Response of Plasma Glucagon to Overnight Fast and Oral Glucose during Normal Pregnancy and in Gestational Diabetes (1974) (59)
Gastric and Pancreatic Release of Somatostatin-like Immunoreactivity During the Gastric Phase of a Meal: Effects of Truncal Vagotomy and Atropine in the Anesthetized Dog (1979) (59)
Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists (2016) (59)
Effect of Insulin Therapy on the Profiles of Plasma Immunoreactive Glucagon in Juvenile-type and Adult-type Diabetics (1978) (59)
The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. (1975) (59)
Molecular and cellular responses of islets during perturbations of glucose homeostasis determined by in situ hybridization histochemistry. (1989) (58)
Klotho-induced insulin resistance: a blessing in disguise? (2006) (58)
Lipotoxicity of-Cells in Obesity and in Other Causes of Fatty Acid Spillover (2001) (57)
Autoantibodies to the GLUT-2 glucose transporter of beta cells in insulin-dependent diabetes mellitus of recent onset. (1993) (56)
Effects of hypoglycemia and prolonged fasting on insulin and glucagon gene expression. Studies with in situ hybridization. (1989) (56)
Abnormal alpha cell function in human diabetes: the response to oral protein. (1978) (56)
Release of pancreatic and gastric somatostatin-like immunoreactivity in response to the octapeptide of cholecystokinin, secretin gastric inhibitory polypeptide, and gastrin-17 in dogs. (1980) (55)
A Study of Glucagonomas by Light and Electron Microscopy and Immunofluorescence (1979) (54)
Studies of the Physiologic Role of Glucagon (1964) (54)
Hyperleptinemia depletes fat from denervated fat tissue. (1999) (54)
Reduced Na+, K+ -ATPase activity in intact red cells and isolated membranes from obese man. (1982) (53)
Studies of the development of diabetic ketosis in the rat. (1972) (53)
Plasma Glucagon Levels During Rapid Exsanguination with and without Adrenergic Blockade (1975) (52)
Radioimmunoassay of glucagon. (1973) (52)
Fasting Levels of Growth Hormone in Men and Women (1965) (52)
Diminished effect of caloric restriction on control of hyperglycemia with increasing known duration of type II diabetes mellitus. (1981) (51)
GLUT-2 function in glucose-unresponsive beta cells of dexamethasone-induced diabetes in rats. (1993) (51)
Multiple forms of somatostatin‐like immunoreactivity in canine pancreas (1978) (51)
The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. (1977) (50)
Antisomatostatin serum increases levels of hormones from the pituitary and gut, but not from the pancreas. (1978) (50)
Carbohydrate metabolism in pregnancy. XIV. Relationships between circulating glucagon, insulin, glucose and amino acids in response to a "mixed meal" in late pregnancy. (1977) (50)
Stimulation of pancreatic immunoreactive somatostatin (IRS) release by glucagon [proceedings]. (1976) (48)
Resistance to adenovirally induced hyperleptinemia in rats. Comparison of ventromedial hypothalamic lesions and mutated leptin receptors. (1998) (48)
Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression. (2000) (48)
Response of pancreatic immunoreactive somatostatin to arginine. (1976) (47)
HIGH GROWTH-HORMONE LEVELS IN DIABETIC KETOACIDOSIS: A POSSIBLE CAUSE OF INSULIN RESISTANCE. (1965) (45)
Lipoapoptosis in Beta-cells of Obese Prediabeticfa/fa Rats (1998) (45)
MitoNEET-Parkin Effects in Pancreatic α- and β-Cells, Cellular Survival, and Intrainsular Cross Talk (2016) (45)
Properties of somatostatin-like immunoreactive polypeptides in the canine extrahypothalamic brain and stomach. (1979) (44)
Glucagon and the insulin: glucagon ratio in severe trauma. (1973) (43)
Structural coupling between pancreatic islet cells (1973) (43)
Effects of gamma-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. (1983) (43)
Properties of immunoreactive glucagon fractions of canine stomach and pancreas. (1977) (42)
Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial (2018) (42)
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. (2004) (42)
Morphine and beta-endorphin influence the secretion of the endocrine pancreas. (1978) (42)
Somatostatin analogs inhibit somatostatin release. (1979) (42)
Coordinate Regulation of Amylin and Insulin Expression in Response to Hypoglycemia and Fasting (1992) (41)
Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma. (1976) (40)
The role of glucagon in diabetes. (1977) (40)
Evidence for a direct effect of insulin on hepatic glucose output. (1959) (40)
Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats (2011) (39)
Half-life of somatostatin-like immunoreactivity in canine plasma. (1979) (38)
Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice (2018) (38)
Role of Leptin in Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Expression* *The nucleotide sequence(s) reported in this paper has been submitted to the GenBank nucleotide sequence databases, with the accession number(s) AB025784. We acknowledge the grant support of the Department o (2000) (38)
Plasma somatostatin-like immunoreactivity during the interdigestive period in the dog. (1981) (38)
Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. (1977) (37)
Studies of the physiology and pathophysiology of the pancreatic D cell. (1978) (36)
Free somatostatin in the circulation: amounts and molecular sizes of somatostatin-like immunoreactivity in portal, aortic, and vena caval plasma of fasting and meal-stimulated dogs. (1980) (36)
Plasma glucagon in nonketotic hyperosmolar coma. (1974) (35)
Bombesin stimulates the release of insulin and glucagon, but not pancreatic somatostatin, from the isolated perfused dog pancreas. (1979) (35)
Effects of leptin, troglitazone, and dietary fat on stearoyl CoA desaturase. (2002) (35)
Characterization of immunoreactive components of insulin and somatostatin in canine pancreatic juice (1979) (34)
Hypergastrinemia in obese noninsulin-dependent diabetes: a possible reflection of high prevalence of vagal dysfunction. (1983) (34)
Effects of dietary carbohydrates on metabolism of calcium and other minerals in normal subjects and patients with noninsulin-dependent diabetes mellitus. (1990) (34)
Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs. (1980) (34)
The milieu interieur and the islets of Langerhans (2004) (34)
Effect of Phenformin on Peripheral Glucose Utilization in Human Diabetic and Nondiabetic Subjects (1960) (33)
Increased insulin resistance in obese, glucose-intolerant Southwestern American Indians: evidence for a defect not explained by obesity. (1980) (33)
Properties of endogenous somatostatin-like immunoreactivity and synthetic somatostatin in dog plasma. (1978) (33)
A new biology of diabetes revealed by leptin. (2015) (32)
Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia. (1993) (32)
Pathophysiology of epidemic St. Louis encephalitis. I. Inappropriate secretion of antidiuretic hormone. II. Pituitary-adrenal function. 3. Cerebral blood flow and metabolism. (1969) (32)
Obesity dysregulates fasting-induced changes in glucagon secretion. (2019) (31)
Pancreatic and gastric release of somatostatinlike immunoreactivity during intestinal phase of a meal. (1979) (31)
Effects of leptin on endothelial function with OB-Rb gene transfer in Zucker fatty rats. (2003) (30)
Immunocytochemical evidence for glucagon-containing cells in the human stomach. (1977) (30)
Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers. (2013) (30)
Insulin-glucagon ratio. (1972) (29)
Combined Leptin Actions on Adipose Tissue and Hypothalamus Are Required to Deplete Adipocyte Fat in Lean Rats (2006) (29)
Effect of endogenous intestinal glucagon-like immunoreactivity (GLI) on insulin secretion and glucose concentration in dogs. (1971) (28)
Extraction of somatostatin from human plasma on octadecylsilyl silica. (1982) (28)
Effect of bombesin upon plasma somatostatin-like immunoreactivity, insulin and glucagon in normal and chemically sympathectomized dogs (1980) (28)
Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine (2013) (28)
Effects of Exogenous Hyperglucagonemia in Insulin-treated Diabetics (1977) (27)
Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets (2021) (27)
Special issue on lipotoxicity. (2010) (27)
Glucagon : physiology, pathophysiology, and morphology of the pancreatic A-cells (1981) (26)
Arginine-Stimulated Hyperglucagonemia in Diabetic Pima Indians (1976) (26)
The effect of calcium and other salts upon the release of glucagon-like immunoreactivity from the gut. (1972) (25)
Demonstration of Glucagon in the Stomach of Human Fetuses (1981) (25)
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes (2017) (25)
Gastric A-cell function in normal dogs. (1976) (25)
Somatostatin Analog‐Induced Remission of Necrolytic Migratory Erythema Without Changes in Plasma Glucagon Concentration (1986) (23)
Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade (2017) (23)
Glucagon and diabetes. (1978) (23)
Leptin Normalizes the Impaired Response of Proinsulin mRNA to Long Chain Fatty Acids in Heterozygous Zucker Diabetic Fatty Rats* (1997) (23)
High Plasma Free Fatty Acid Levels Contribute to the Hypersomatostatinemia of Insulin Deficiency (1981) (23)
Tolbutamide-phenformin in ketoacidosis-resistant patients. (1960) (22)
Normal glucagon response to arginine infusion in "prediabetic" Pima Indians. (1976) (22)
Hyperglucagonaemia after burns. (1974) (21)
Gastric function and obesity: gastric emptying, gastric acid secretion, and plasma pepsinogen. (1984) (21)
Effect of exogenous and endogenous prostaglandin E upon gastric endocrine function in dogs. (1980) (21)
Glucoregulatory Hormones in Health and Disease: A Teleologic Model (1966) (21)
Glucagon therapeutics: Dawn of a new era for diabetes care (2016) (20)
Nonthyroidal control of metabolism after burn injury: Possible role of glucagon (1985) (19)
Post-GLUT-2 defects in beta-cells of non-insulin-dependent diabetic obese rats. (1994) (19)
Comparison of the effects of insulin and orinase (tolbutamide) on peripheral glucose utilization in the dog. (1958) (19)
Release of gastric somatostatin-like immunoreactivity during acidification of the duodenal bulb. (1979) (19)
Characterization of somatostatin-like components in the tumors and plasma of a patient with a somatostatinoma. (1981) (19)
Glucagon responses of isolated α cells to glucose, insulin, somatostatin, and leptin. (2011) (18)
New ideas concerning the physiologic roles of glucagon. (1968) (18)
Inhibition of Glucagon Secretion by Exogenous Glucagon in the Isolated, Perfused Dog Pancreas (1982) (17)
Oral administration of somatostatin reduces postprandial plasma triglycerides, gastrin and gut glucagon-like immunoreactivity. (1979) (17)
Somatostatin analogs as glucagon suppressants in diabetes. (1978) (17)
Morphologic and Functional Changes in Sympathetic Nerve Relationships With Pancreatic α-Cells After Destruction of β-Cells in Rats (1987) (17)
Demonstration of reverse fatty acid transport from rat cardiomyocytes Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400237-JLR200 (2004) (17)
The milieu interieur and the islets of Langerhans (1981) (16)
Release of somatostatin-like immunoreactivity from the lower gut. (1979) (16)
Effect of intravenously administered glucose on glucagon and insulin secretion during fat absorption. (1975) (16)
The role of glucagon deficiency in the Houssay phenomenon of dogs. (1978) (16)
Effects of neurotensin and substance P on insulin and glucagon release by the perfused dog pancreas [proceedings]. (1976) (16)
Hyperinsulinemia in obesity: lack of relation to gastric emptying of glucose solution or to plasma somatostatin levels. (1983) (16)
Biological and immunological activity of pancreatic glucagon and enteric glucagon-like immunoreactivity. (1974) (16)
THE EFFECTS OF COCL-2 ON GLUCAGON LEVELS IN PLASMA AND PANCREAS OF THE RAT. (1964) (15)
Role of histamine H2-receptors in gastric and pancreatic release of somatostatin-like immunoreactivity during the gastric phase of a meal (1981) (15)
Hepatic autography in uncontrolled experimental diabetes and its relationships to insulin and glucagon. (1974) (15)
Secretin Inhibits Glucagon in the Isolated Perfused Dog Pancreas (1983) (15)
Effect of prostaglandin E2 upon release of pancreatic somatostatin-like immunoreactivity. (1981) (15)
Plasma Somatostatin-like immunoreactivity in chemically sympathectomized dogs. (1980) (15)
Glucagon in Diabetes Mellitus (1983) (15)
Rapid changes in hepatic glucose output after a pulse of growth hormone in dogs. (1984) (15)
Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes. (1979) (15)
Insulin Inhibits Somatostatin-Like Immunoreactivity Release Stimulated by Intragastric HCI (1981) (14)
Nocturnal hypoglycemia in aggressively controlled diabetes. (1982) (14)
Role of Nitric Oxide in Obesity-induced b Cell Disease (1997) (14)
Effect of 2-deoxy-D-glucose on plasma somatostatin levels in conscious dogs. (1981) (14)
Immunocytochemical characterization of secretory granule maturation in pancreatic A-cells. (1984) (14)
Glucagon- and Glicentin-Producing Cells (1983) (13)
Fatty diabetic lung: functional impairment in a model of metabolic syndrome. (2010) (13)
Control of pancreatic glucagon secretion by glucose. (1968) (13)
Normal Insulin Sensitivity of the Islets of Langerhans in Obese Subjects with Resistance to Its Glucoregulatory Actions (1984) (13)
Defective Fatty Acid-mediated -Cell Compensation in Zucker Diabetic Fatty Rats (1996) (12)
Classification of Genetic Diabetes Mellitus (1967) (12)
Effect of dog jejunum "glucagon-like immunoreactive material" on adipose tissue metabolism. (1969) (12)
Effect of atropine on plasma gastrin and somatostatin concentrations during sham feeding in man (1985) (12)
The effects of glucagon administration to nondiabetics and diabetics. (1976) (12)
The organ of Langerhans in new perspective. (1970) (12)
Beta-cell GLUT-2 loss and non-insulin-dependent diabetes mellitus: current status of the hypothesis. (1993) (12)
Characteristics of tissue IRGs in the dog. (1976) (12)
Inhibition of alanine-stimulated glucagon secretion by secretin in the dog. (1973) (11)
Origin of peripheral venous hypersomatostatinemia in alloxan-diabetic dogs. (1981) (11)
The glycogenolytic activity of immunoreactive pancreatic glucagon in plasma. (1971) (11)
Secretory patterns of glucoregulatory hormones in prehepatic circulation of dogs. (1985) (11)
Demonstration of gastric glucagon hypersecretion in insulin-deprived alloxan-diabetic dogs. (1977) (11)
Glucagon and diabetes mellitus. (1972) (10)
Pancreatic glucagon in health and disease. (1971) (10)
Pancreatic -Cells in Obesity (1995) (10)
Nonthyroidal control of metabolism after burn injury: possible role of glucagon. (1986) (10)
THE INTRAVENOUS TOLBUTAMIDE RESPONSE TEST IN THE DIAGNOSIS OF MILD DIABETES (1959) (10)
Alveolar–capillary adaptation to chronic hypoxia in the fatty lung (2015) (10)
Evidence for an insulin-independent alpha-cell abnormality in human diabetes. (1976) (9)
The effect of short-term intravenous insulin administration on the glucagon response to a carbohydrate meal in adult onset and juvenile type diabetes (1977) (9)
THE CELLULAR ORIGIN OF PANCREATIC GLUCAGON (1970) (9)
Glucagon and insulin: a bihormonal system. (1976) (9)
GLUCAGON IN PATHOGENESIS OF DIABETES (1975) (9)
Morphologic and functional changes in sympathetic nerve relationships with pancreatic alpha-cells after destruction of beta-cells in rats. (1987) (9)
Compensatory capabilities of islets of BB/Wor rats exposed to sustained hyperglycemia. (1990) (9)
Slow recovery of body fat lost during adenovirus-induced hyperleptinemia. (2000) (8)
Separation of Human Insulin, Glucagon and Other Pancreatic Proteins (1964) (8)
The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat (1975) (8)
Synthesis and biological activity of glycosylated analogs of somatostatin. (1979) (8)
Erratum: A novel leptin receptor isoform in rat (FEBS Letters 392 (1996) (87-90)) (PII S0014579396007909) (1996) (8)
EVIDENCE FOR THE PRESENCE OF CLUCAGON-LIKE IMMUNOREACTIVITY (CLI) IN THE PANCREAS1 (1976) (7)
Follow-up of a patient with somatostatinoma. (1986) (7)
Pancreatic Alpha Cell Autoantibodies and Glucagon Response to Arginine (1984) (7)
Hyperglucagonemia following thermal injury: insulin and glucagon in the posttraumatic catabolic state. (1973) (7)
The molecular forms of immunoreactive glucagon secreted by the isolated, perfused dog pancreas. (1978) (7)
Plasma somatostatin-like immunoreactivity in depancreatized dogs. (1979) (7)
Triglyceride lowering effect of somatostatin and its analogs (1977) (7)
Glucagon and Blood Sugar (1976) (7)
An AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production (2016) (7)
Independence of hyperleptinemia-induced fat disappearance from thyroid hormone. (2004) (6)
The effects of acute and chronic insulin administration on plasma IRG levels in human diabetes. (1976) (6)
Adiposity of the Heart (2006) (6)
Pancreatic and gastric D cell function in hypophysectomized dogs. (1979) (6)
Effects of exogenous glucagon in insulin treated diabetics (1976) (6)
Glucagon and Somatostatin (1978) (6)
Interrelations of glucose, insulin and glucagon after overnight fast and in response to oral glucose during late pregnancy. (1975) (6)
Candidate hormones of the gut. XIV. Enteroglucagon. (1974) (6)
Further electron microscopic studies of diabetic microangiopathy. (1970) (6)
Factors regulating islet regeneration in the post-insulinoma NEDH rat. (1992) (6)
Inhibitory effect of intragastric glucose on gastric acid secretion and gastric emptying of liquids in man (1983) (5)
Kassinin: stimulation of insulin and glucagon secretion in the rat. (1982) (5)
Glucagon antagonism in islet cell proliferation (2017) (5)
Somatostatin, a physiologic regulator of nutrient influx (1977) (5)
Opposing actions of glucagon and insulin on splanchnic d cell function. (1983) (5)
Protecting the Heart From Lipid Overload (2005) (5)
Role of glucagon in diabetes. (1977) (5)
Role of pancreatic somatostatin in nutrient homeostasis (1978) (5)
RELATIVE EFFECTIVENESS OF NEWER ORAL AGENTS IN THE REGULATION OF DIABETIC PATIENTS IMPERFECTLY CONTROLLED BY TOLBUTAMIDE STUDIED WITHIN THE FRAMEWORK OF A TENTATIVE SUBCLASSIFICATION OF THE DISEASE (1959) (5)
Effect of acute hyperkalemia on plasma insulin and glucagon. (1971) (5)
Benefits and risks of meticulous control of diabetes. (1982) (5)
Effects of gut hormone on insulin and glucagon secretion (1968) (5)
How adipocytes integrate surplus caloric intake with caloric storage: Lessons from Morgan Spurlock and some French geese (2004) (5)
Alternative Conceptions of Sex (and Sex Differences) (1993) (4)
SOMATOSTATIN IS DECREASED IN THE NEUROHYPOPHYSIS OF THE BRATTLEBORO RAT AND MAY PLAY A ROLE IN THE REGULATION OF VASOPRESSIN SECRETION (1982) (4)
Ultrastructural detection of granulated cells in the autonomic ganglia of the rat pancreas (1985) (4)
Preparation of high specific activity glucagon I131 (1962) (4)
Morphometric and functional studies of islets in diabetes-prone BB/W rats that are discordant for overt diabetes (1989) (4)
Insulin glucagon ration. (1971) (4)
Evidence for the presence of glucagon-like immunoreactivity (GLI) in the pancreas. (1976) (4)
Adiposity of the heart. Authors' reply (2006) (4)
Fasting and postprandial plasma glucagon and glucagon-like immunoreactivity are normal in obese Pima Indians. (1983) (4)
Regulation of a 8-cell glucose transporter gene expression (4)
Role of H2-receptors in gastrogenic hyperglycemia and hyperinsulinemia in dogs (1982) (4)
Possible role of insulin-stimulating hormones in disturbances of nutrient tolerance. (1970) (4)
Ligand leakage from immunoaffinity column. (1983) (4)
Effects of carbohydrate deprivation. (1972) (4)
Erratum: Correction: "Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway," (Proc Natl Acad Sci USA (2015) 112:8 (2503-2508) DOI: 10.1073/pnas.1424934112) (2015) (4)
Glucagon Secreting Pancreatic Tumor: A New Entity. (1966) (3)
Lack of a "big plasma glucagon" response during arginine stimulation of glucagon secretion. (1982) (3)
Evidence for a regulatory role of the stomach in islet cell function. (1979) (3)
Movin' on up: adipocytes become regulators of nutrient homeostasis. (2006) (3)
[Role of the glut 2 transporters in the pathogenesis of type II diabetes]. (1992) (3)
Gastric emptying: an important regulatory factor in postprandial insulin release [proceedings]. (1980) (3)
Responses of the endocrine pancreas to morphine and β-endorphin (1978) (3)
PHYSIOLOGY IN MEDICINE: A SERIES OF ARTICLES LINKING MEDICINE WITH SCIENCE (2005) (3)
Role of Fibroblast Growth Factor 21 in Biology of Glucagon (2013) (3)
Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. (1997) (3)
Erratum: Underexpression of β cell high K(m) glucose transporters in noninsulin-dependent diabetes (Science (26 Oct. 1990) (546)) (1990) (3)
Insulin (I), glucagon (G), and the I/G ratio in carbohydrate (CHO) induced hyperlipemia (1974) (3)
Normal and abnormal alpha cell function. (1973) (3)
Noninvasive assessment of alveolar microvascular recruitment in conscious non-sedated rats (2014) (3)
The proper choice of oral antihyperglycemic therpy in diabetes mellitus. (1961) (3)
Glucagon Secretion, Function, and Clinical Role (1982) (2)
PANCREATIC GLUCAGON SECRETION (1970) (2)
Perspectives in Diabetes Lipotoxicity in the Pathogenesis of Obesity-Dependent (1995) (2)
Gastric glucagon release during gastric and intestinal phase of a meal in dogs. (1980) (2)
The effect of prolonged somatostatin infusion on hemostasis (1977) (2)
Physiological role of CCK, secretin and GIP in pancreatic and gastric somatostatin release (1978) (2)
Sympathectomy and prostaglandin deficiency do not prevent gastrogenic hyperglycaemia and hyperinsulinaemia. (1979) (2)
Current status of aryl sulfonylureas in treatment of diabetes mellitus. (1956) (2)
[Maurice Dérot Prize 2001. The liporegulator system and disease]. (2001) (2)
Dermorphin: an opioid peptide from amphibian skin which affects endocrine pancreatic function. (1983) (2)
Hylambatin, a structurally unique tachykinin: effects on insulin and glucagon secretion. (1984) (2)
Characterization of the glucagon-like polypeptides released by the dog gut into the circulation [proceedings]. (1980) (2)
Pancreatic somatostatin-like immunoreactivity suppresses gastric acid secretion in rats. (1979) (2)
Gastric glucagon secretion. (1976) (2)
Effect of acetylcholine infusion upon the release of gastric and pancreatic somatostatin-like immunoreactivity (SLI) (1980) (2)
Origin of hypersomatostatinaemia in alloxan diabetic-dogs (1980) (2)
Insulin inhibition of insulin secretion. (1982) (2)
Role of insulin lack in the abnormal glucagon (IRG) response in human diabetes (1977) (1)
[New findings on the mechanisms of secretion of glucagon]. (1985) (1)
Insulin Therapy and Lipid Overload in Type 2 Diabetes—Reply (2008) (1)
Second Annual Meeting of the European Association for the Study of Diabetes abstracts (1966) (1)
Increased plasma immunoreactive somatostatin (IRS) levels in alloxan diabetic dogs and juvenile diabetic humans (1977) (1)
Fasting-Induced Changes in Glucagon Secretion Are Dysregulated in Obesity (2018) (1)
Noninvasive tracking of gene expression by reporter transgene imaging (2008) (1)
REGULATION OF GLUCAGON RELEASE IN VIVO (1970) (1)
P-436: Fatty heart disease - myocardial steatosis in humans (2002) (1)
Gastrointestinal hormones and somatostatin release (1978) (1)
GLUT-2 and the pathogenesis of Type II diabetes (1992) (1)
Kassinin and substance P stimulate somatostatin release in the rat. (1981) (1)
Glucagon II (1983) (1)
The essential role of glucagon in diabetic hyperglycemia and the effect of glucagon blockade in diabetes mellitus (1974) (1)
The Apparent Superiority of Tolbutamide Over Insulin in the Regulation of Selected Clinic Patients (1958) (1)
Insulin binding to human erythrocytes decreases as a function of cell age (1979) (1)
Effect of insulin and somatostatin on A cell dysfunction in human diabetes (1976) (1)
Gastric α cell function in normal and diabetic dogs (1975) (1)
The Physiologic Roles of Pancreatic Glucagon and a Gastrointestinal Glucagon-like Hormone (1968) (1)
Humans: New Insights from Magnetic Resonance Spectroscopy Unraveling the Cellular Mechanism of Insulin Resistance in (2015) (1)
Regulation of fatty acid homeost (2016) (1)
Response of plasma somatostatin-like immunoreactivity to the administration of alloxan in dogs. (1979) (1)
Characterization of α cell dysfunction in human diabetes (1975) (1)
Absence of glucopenic inhibition of the insulin response to arginine at the onset of diabetes in BB/W rats (1988) (1)
The Effects of Exogenously Induced Hyperglucagonemia in Insulin-Treated Diabetics (1977) (1)
Plasma Somatostatin-like Immunoreactivity during (1981) (1)
Impaired Lung Function In Conscious Non-Sedated Fatty Diabetic Rats Measured By A Rebreathing Technique (2012) (0)
Variations of Metabolic Rate and Hormone Concentrations After Burns (1983) (0)
DIABETES MELLITUS-DIAGNOSIS AND TREATMENT (1968) (0)
Chlorpropamide and Tolbutamide-Reply (1961) (0)
A method for determining the presence of diabetes-associated antibodies or antibodies øcellerettede (1992) (0)
[Possible role of pancreatic hormones insulin and glucagon and enteroglucagon in postprandial lipid metabolism]. (1973) (0)
[Activity of somatostatin-containing cells of the Ilets of Langerhans in experimental diabetes]. (1975) (0)
reactive Pancreatic Glucagon in Plasma (1971) (0)
[Functional interrelations of the islets]. (1984) (0)
PREPARATION OF HIGH SPECIFIC ACTIVITY GLUCAGON I$sup 13$$sup 1$ (1962) (0)
Somatostatin-like polypeptides in the plasma and tissues of a patient with a somatostatin-producing tumour. (1980) (0)
A-cell insensitivity to somatostatin and paradoxical stimulation of glucagon secretion by somatostatin in alloxan diabetic pancreases (1982) (0)
Cardiac dose response relationship to glucagon in normal intact dogs and men (1976) (0)
Growth hormone and growth hormone secreting tumors of the pituitary ("acromegaly") (1967) (0)
Role of prostaglandins in gastric endocrine function (1979) (0)
The primacy of insulin. (1977) (0)
How pancreatic glucagon can affect health. (1973) (0)
Erratum: A new biology of diabetes revealed by leptin (Cell Metabolism (2015) 21 (15-20)) (2015) (0)
Demonstration in man of a correlation between insulin binding and insulin action in peripheral tissues (1959) (0)
Abnormal Glucagon Secretion in Diabetes Mellitus. (1970) (0)
Precursors of the islet hormones in pancreatic juice (1979) (0)
The management of type I diabetes in the 1980's (1980) (0)
Stimulation of gastric and pancreatic somatostatin release by HCl (1978) (0)
Somatostatin in the hypothalmo-neurohypophysial system of Long-Evans and Brattleboro rats (1982) (0)
Role of adrenergic innervation in postprandial release of somatostatin-like immunoreactivity (SLI) (1979) (0)
Physiologic significance of the secretion of insulin into the portal circulation: Comparison of the metabolic effects of insulin after administration by intraportal and systemic routes (1958) (0)
Alpha cell dysfunction in human diabetes (1975) (0)
Qualitative differences in the biologic effects of physiologic amounts of intraportally and peripherally infused somatostatin (1978) (0)
Gastric and pancreatic somatostatin release during the gastric phase of a meal: A gastro-insular axis (1978) (0)
The effect of glucose on glucagon and insulin secretion during a fat meal (1973) (0)
Dissecting the actions of widely used diabetes drugs (2013) (0)
[Immunocytochemical identification of the glucagon-secreting cells in gastric mucosa]. (1976) (0)
Glucagon, pancreatectomy and ketoacidosis. (1977) (0)
Recent advances on the control of glucagon secretion (1985) (0)
Proc. V Int. Congr. Endocrinology, Vol. II (1977) (0)
Medical emergencies in diabetes. (1962) (0)
Divergent regulation of sense and antisense erythropoietin receptor transcripts (asEPOR) in obesity‐associated diabetes mellitus (2012) (0)
ROLE OF PANCREATIC BETA-CELL FUNCTION ON A-CELL RESPONSE TO HYPOGLYCEMIA IN MAN (1983) (0)
[Recent studies on the physiology of glucagon]. (1967) (0)
Panel Discussion: Intracellular Detection of Hormones by Immunochemical Means (2008) (0)
GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON blood of man and dog (2013) (0)
Pioglitazone Does Not Reverse Established Lung Dysfunction In Fatty Diabetic Rats (2012) (0)
Inadequacy of fat cells: mechanisms and management of America's major health problem (2007) (0)
Etiopathogenesis type I and type II diabetes: reclassifications and interventions? (1984) (0)
THE REGULATION OF METABOLISM (1978) (0)
[Effects of gut hormone on insulin and glucagon secretion]. (1968) (0)
Demonstration of the Hormonal Status of Endogenous Glucagon (2008) (0)
Role of pancreas in postprandial secretion of somatostatin-like immunoreactivity (1978) (0)
Control of fuel fluxes by polypeptides. (1980) (0)
Homologous serum hepatitis as a complication of transfusion. (1955) (0)

This paper list is powered by the following services:

Other Resources About Roger Unger

en.wikipedia.org

What Schools Are Affiliated With Roger Unger?

Roger Unger is affiliated with the following schools: